FDA Warns Exosome Maker for Marketing Outside Its IND
(MedPage Today) -- The FDA has warned Kimera Labs that it can't sell its exosome product for uses outside of its recently secured investigational new drug (IND) application.
In a warning letter that was posted to the FDA's website last September...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | International Medicine & Public Health | Investigational New Drugs | Marketing | Warnings | Websites